



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Methyclothiazide

Chemical Properties


CAS No. : 135-07-9

Formula: C₉H₁₁Cl₂N₃O₄S₂

Molecular Weight: 360.24

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Methyclothiazide (Aquatensen) is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease.
Targets(IC50)	Others,Carbonic Anhydrase
In vitro	Methyclothiazide (0.1 mM) reduces Ca ²⁺ contractures with maximal inhibition of 90.4% in SHR aortic rings with endothelium. The inhibitory effect of Methyclothiazide (0.1 mM) on Ca ²⁺ contracture is significantly but not totally abolished by the NO synthase inhibitor in SHR aortic rings with functional endothelium. [1] Methyclothiazide (0.1 mM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from spontaneously hypertensive rats (SHR) rather than normotensive Wistar Kyoto rats (WKY), and the maximal vasoconstrictive effect of NE and AVP is decreased by 59% and 32.3%, respectively. [2] Methyclothiazide (3.5 mM) inhibits renin release in rat kidney slices. [3]
In vivo	Methyclothiazide (0.1 g/L for the first 5 weeks and 0.2 g/L for the second 2 weeks, drinking water) attenuates development of hypertension in salt-sensitive (DS) rats, but does not affect blood pressure in salt-resistant (DR) ones. [4] The methyclothiazide-treated DOCA-salt rats weigh less than controls or the nonsupplemented DOCA-salt rats at weeks 3 and 4. Methyclothiazide added to the drinking water of DOCA-salt rats attenuates the elevation of blood pressure. [5]

Solubility Information

Solubility	DMSO: 72 mg/mL (199.86 mM), H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 4 mg/mL (11.1 mM), < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7759 mL	13.8796 mL	27.7593 mL
5 mM	0.5552 mL	2.7759 mL	5.5519 mL
10 mM	0.2776 mL	1.388 mL	2.7759 mL
50 mM	0.0555 mL	0.2776 mL	0.5552 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Colas B, et al. Eur J Pharmacol, 2000, 408(1), 63-67.

Colas B, et al. Fundam Clin Pharmacol, 2000, 14(4), 363-368.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481